-
¿¹Ö×Áöanti-tumorÖ÷ҪרעÓÚ³£¼û¶ñÐÔÖ×ÁöÁìÓòµÄÐÂÒ©Ñз¢£¬£¬ £¬ £¬£¬£¬£¬ÔÚÑÐÏîÄ¿°üÀ¨1 ÀàÐÂÒ©HS-20106×¢ÉäÒº¡¢HS-20105¡¢HS-20117¡¢HS-10516½ºÄÒ¡¢HS-10382Ƭ¡¢HS-10370Ƭ¡¢HS-10386Ƭ¡¢HS-10502Ƭ¡¢HS-10365½ºÄÒ¡¢×¢ÉäÓÃHS-20089/HS-20093¡¢HS-10375Ƭ¡¢HS-10381½ºÄҵȡ£¡£¡£¡£¡£Ïàʶ¸ü¶à +
¿¹Ö×ÁöÖ÷ҪרעÓÚ³£¼û¶ñÐÔÖ×ÁöÁìÓòµÄÐÂÒ©Ñз¢£¬£¬ £¬ £¬£¬£¬£¬ÔÚÑÐÏîÄ¿°üÀ¨1 ÀàÐÂÒ©HS-20106×¢ÉäÒº¡¢HS-20105¡¢HS-20117¡¢HS-10516½ºÄÒ¡¢HS-10382Ƭ¡¢HS-10370Ƭ¡¢HS-10386Ƭ¡¢HS-10502Ƭ¡¢HS-10365½ºÄÒ¡¢×¢ÉäÓÃHS-20089/HS-20093¡¢HS-10375Ƭ¡¢HS-10381½ºÄҵȡ£¡£¡£¡£¡£Ïàʶ¸ü¶à + -
¿¹Ñ¬È¾anti-infectivesÖ÷ҪרעÓÚ¿¹²¡¶¾¡¢¿¹ÖØ´óϸ¾úѬȾ¡¢¿¹Õæ¾úѬȾÁìÓòµÄÐÂÒ©Ñз¢£¬£¬ £¬ £¬£¬£¬£¬ÔÚÑÐÏîÄ¿°üÀ¨ÄâÓÃÓÚÖÎÁÆÖйú³ÉÄêÍâÒõÒõµÀÄîÖé¾ú²¡£¡£¡£¡£¡£¨VVC£©µÄHS-10366ƬµÈ¡£¡£¡£¡£¡£Ïàʶ¸ü¶à +
¿¹Ñ¬È¾Ö÷ҪרעÓÚ¿¹²¡¶¾¡¢¿¹ÖØ´óϸ¾úѬȾ¡¢¿¹Õæ¾úѬȾÁìÓòµÄÐÂÒ©Ñз¢£¬£¬ £¬ £¬£¬£¬£¬ÔÚÑÐÏîÄ¿°üÀ¨ÄâÓÃÓÚÖÎÁÆÖйú³ÉÄêÍâÒõÒõµÀÄîÖé¾ú²¡£¡£¡£¡£¡£¨VVC£©µÄHS-10366ƬµÈ¡£¡£¡£¡£¡£Ïàʶ¸ü¶à + -
ÖÐÊàÉñ¾CNS diseasesÖ÷ҪרעÓÚ¾«Éñ¼²²¡¡¢Éñ¾ÏµÍ³¼²²¡µÈÁìÓòµÄÐÂÒ©Ñз¢£¬£¬ £¬ £¬£¬£¬£¬ÔÚÑÐÏîÄ¿°üÀ¨ÄâÓÃÓÚÖÎÁƾ«ÉñÆÆËéÖ¢µÄ1 ÀàÐÂÒ©HS-10380Ƭ¡¢HS-10506ƬµÈ¡£¡£¡£¡£¡£Ïàʶ¸ü¶à +
ÖÐÊàÉñ¾Ö÷ҪרעÓÚ¾«Éñ¼²²¡¡¢Éñ¾ÏµÍ³¼²²¡µÈÁìÓòµÄÐÂÒ©Ñз¢£¬£¬ £¬ £¬£¬£¬£¬ÔÚÑÐÏîÄ¿°üÀ¨ÄâÓÃÓÚÖÎÁƾ«ÉñÆÆËéÖ¢µÄ1 ÀàÐÂÒ©HS-10380Ƭ¡¢HS-10506ƬµÈ¡£¡£¡£¡£¡£Ïàʶ¸ü¶à + -
´úл¼°ÆäËümetabolic diseasesÖ÷ҪרעÓÚÌÇÄò²¡¡¢·ÊÅֵȴúлÐÔ¼²²¡ÁìÓòµÄÐÂÒ©Ñз¢£¬£¬ £¬ £¬£¬£¬£¬ÔÚÑÐÏîÄ¿°üÀ¨1ÀàÐÂÒ©HS-10511Ƭ¡¢HS-20094×¢ÉäÒº¡¢HS-10384 Ƭ¡¢HS-10518½ºÄҵȡ£¡£¡£¡£¡£Ïàʶ¸ü¶à +
´úл¼°ÆäËüÖ÷ҪרעÓÚÌÇÄò²¡¡¢·ÊÅֵȴúлÐÔ¼²²¡ÁìÓòµÄÐÂÒ©Ñз¢£¬£¬ £¬ £¬£¬£¬£¬ÔÚÑÐÏîÄ¿°üÀ¨1ÀàÐÂÒ©HS-10511Ƭ¡¢HS-20094×¢ÉäÒº¡¢HS-10384 Ƭ¡¢HS-10518½ºÄҵȡ£¡£¡£¡£¡£Ïàʶ¸ü¶à + -
×ÔÉíÃâÒßautoimmune diseasesÖ÷ҪרעÓÚ×ÔÉíÃâÒßϵͳ¼²²¡ÁìÓòµÄÐÂÒ©Ñз¢£¬£¬ £¬ £¬£¬£¬£¬Èç1ÀàÐÂÒ©HS-10374ƬµÈ¡£¡£¡£¡£¡£Ïàʶ¸ü¶à +
×ÔÉíÃâÒßÖ÷ҪרעÓÚ×ÔÉíÃâÒßϵͳ¼²²¡ÁìÓòµÄÐÂÒ©Ñз¢£¬£¬ £¬ £¬£¬£¬£¬Èç1ÀàÐÂÒ©HS-10374ƬµÈ¡£¡£¡£¡£¡£Ïàʶ¸ü¶à +
¼ò
¤™
- ¼ò
- ·±
- EN
-
¹ØÓÚvic3308 ¤™
-
¿Æ¼¼Á¢Òì ¤™
-
²úÆ·ÓëÓªÒµ ¤™
-
ÐÂÎÅÖÐÐÄ ¤™
-
Ͷ×ÊÕß¹Øϵ ¤™
-
ESG ¤™
-
Ö°ÒµÉú³¤ ¤™
